MarketBeat is an American financial media company headquartered in Sioux Falls, South Dakota, founded in 2011 by Matthew Paulson as Analyst Ratings Network before rebranding in 2015. The company operates an online platform that delivers real-time financial data, market analysis, and news, aiming to empower individual investors with tools to make informed trading decisions.
Black Rock Coffee Bar (NASDAQ:BRCB) executives outlined the company’s growth strategy, store economics and competitive positioning during a William Blair consumer event, emphasizing plans to sustain rapid unit expansion while leaning on customer loyalty, store-level execution and a differentiated ca
Backblaze (NASDAQ:BLZE) Chief Executive Gleb Budman said the cloud storage company is seeing a material shift in demand tied to artificial intelligence workloads, as customers seek alternatives to hyperscaler platforms and newer AI-focused cloud providers look to add storage capabilities.
Speaking
Blackbaud (NASDAQ:BLKB) executives emphasized the company’s nonprofit software focus, artificial intelligence initiatives, payments opportunity and capital return strategy during a discussion hosted by Baird Senior Research Analyst Rob Oliver.
Oliver described Blackbaud as a vertical software leade
IREN Limited is pivoting from Bitcoin mining to AI infrastructure, securing an 800MW data center campus in Australia and a $3.65 billion Microsoft-backed financing facility.
BlackLine (NASDAQ:BL) executives said the company is leaning on platform pricing, artificial intelligence and deeper enterprise adoption as it works to reaccelerate revenue growth, according to remarks at a William Blair conference session.
Chair and CEO Owen Ryan described BlackLine as a “mission-
U.S. EV sales fell 27% in Q1 2026 after federal tax credits ended, creating diverging outlooks for Rivian, Lucid, and Tesla amid continued global EV growth.
BioAge Labs (NASDAQ:BIOA) executives used a fireside chat at the Jefferies 2026 Global Healthcare Conference to outline the company’s plans for BGE-102, its lead NLRP3 inhibitor, with near-term readouts expected in cardiovascular risk and diabetic macular edema.
The company’s chief business officer
Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR mutations, Chief Executive Officer Mark Velleca said during a Jefferies fireside chat following the company
BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth expectations for hereditary angioedema drug ORLADEYO, progress for late-stage HAE candidate navenibart
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive disorder and advance a broad central nervous system pipeline.
Speaking at a Jefferies fireside chat
Axon Enterprise (NASDAQ:AXON) President Josh Isner said the company continues to see durable growth opportunities across public safety, international markets, enterprise customers and new artificial intelligence products, speaking during a William Blair & Company fireside chat hosted by research
Avalyn Pharma (NASDAQ:AVLN) executives outlined the company’s inhaled pulmonary fibrosis strategy at the Jefferies Global Healthcare Conference, emphasizing its recent IPO, ongoing mid-stage studies and plans to position its candidates as potential backbone therapies for idiopathic pulmonary fibrosi
AeroVironment (NASDAQ:AVAV) executives told investors at William Blair’s 46th Annual Growth Stock Conference that the company sees expanding opportunities across drones, loitering munitions and counter-drone systems, while also emphasizing ongoing capacity investments tied to programs such as Switch
Assembly Biosciences (NASDAQ:ASMB) is awaiting a key development plan from partner Gilead Sciences for its herpes simplex virus programs while advancing ABI-6250 into multiple liver disease indications, Chief Executive Officer Jason Okazaki said during a Jefferies biotech event.
Okazaki said 2024 w
Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives outlined upcoming clinical catalysts, early commercial trends and pipeline priorities during a Jefferies fireside chat, with Chief Medical Officer James Hamilton emphasizing that the company remains focused exclusively on siRNA therapeutics through
Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m
Quanex Building Products (NYSE:NX) reported a modest increase in fiscal second-quarter revenue but sharply lower earnings, as inflation in raw materials, freight and logistics weighed on margins and led the company to withhold reaffirmation of its prior full-year outlook.
On the company’s earnings
Navitas Semiconductor solves severe thermal bottlenecks in artificial intelligence server racks by fundamentally transforming power delivery architecture.
StealthGas (NASDAQ:GASS) reported higher first-quarter revenue and continued to emphasize its debt-free balance sheet, growing cash position and charter coverage during its first-quarter 2026 earnings call.
Chairman Michael Jolliffe said revenue rose to $42.8 million in the quarter, up 2% from $42
Saputo (TSE:SAP) executives said the dairy processor ended fiscal 2026 with stronger margins, improved cash generation and a more focused portfolio, even as lower U.S. dairy commodity pricing weighed on reported revenue in the fourth quarter.
On the company’s fourth-quarter earnings call, President
ABM Industries (NYSE:ABM) reported stronger second-quarter fiscal 2026 revenue growth and record first-half new sales bookings, while management maintained its full-year adjusted earnings outlook and said it expects a stronger margin performance in the second half of the year.
President and Chief E
G-III Apparel Group (NASDAQ:GIII) reported first-quarter fiscal 2027 results that exceeded its own expectations, as stronger gross margins and growth in its go-forward brand portfolio helped offset the planned loss of revenue tied to PVH brands.
Chairman and Chief Executive Officer Morris Goldfarb
Five Below fell more than 13% after Q1 2026 earnings beat estimates, as cautious second-half guidance and tariff uncertainty overshadowed strong revenue and EPS results.
Arrow Financial (NASDAQ:AROW) used its virtual annual meeting to highlight what executives described as a transformational 2025, including the first full year operating under the unified Arrow Bank brand, stronger profitability metrics and progress toward its planned acquisition of Adirondack Bank.
Tuniu (NASDAQ:TOUR) reported higher first-quarter revenue and its fifth consecutive quarter of non-GAAP profitability, as management said China’s travel market continued to benefit from solid demand during the period, including support from the longest Chinese New Year holiday on record.
Founder, C
Broadcom secures massive custom silicon demand as hyperscalers pour unprecedented capital into artificial intelligence infrastructure across the globe.
argenx (NASDAQ:ARGX) Chief Financial Officer Karl Gubitz told investors at the 46th Annual William Blair Growth Stock Conference that the biotechnology company remains focused on revenue growth, profitability and execution as it expands the VYVGART franchise and advances additional pipeline assets.
Arcturus Therapeutics (NASDAQ:ARCT) President and CEO Joseph Payne outlined the company’s messenger RNA programs, vaccine approvals and upcoming clinical milestones during a presentation at the Jefferies Global Healthcare Conference in New York.
Payne described Arcturus as a “next generation messen
Amgen (NASDAQ:AMGN) executives used a Jefferies investor conference appearance to emphasize the company’s first-quarter growth, its late-stage pipeline and its preparations for potential launches, including the obesity candidate MariTide.
Peter Griffith, executive vice president and chief financial
Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global Healthcare Conference in New York.
Speaking with Jefferies analyst Marco Baruzzi, Wessman said Alvotech ha
Altimmune (NASDAQ:ALT) executives said the company is preparing to begin enrolling patients in the second half of the year for a Phase 3 trial of pemvidutide in metabolic dysfunction-associated steatohepatitis, or MASH, while also awaiting data from related alcohol-associated liver disease programs.
Align Technology (NASDAQ:ALGN) CFO John Morici said the company continues to navigate a challenging but stable demand environment, with international markets and dental service organizations offsetting pressure in parts of North America.
Speaking at the Jefferies Global Healthcare Conference in a f
Aldeyra Therapeutics (NASDAQ:ALDX) Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions.
Speaking at a Jefferies fireside c
Akebia Therapeutics (NASDAQ:AKBA) outlined its commercial priorities for Vafseo, the expected evolution of reimbursement after the TDAPA period and several renal-disease pipeline programs during a fireside chat at the Jefferies 2026 Global Healthcare Conference.
Erik, Akebia’s chief financial offic
Rubrik (NYSE:RBRK) reported what executives described as a record first quarter of fiscal 2027, exceeding its guided metrics and raising its full-year outlook as the cybersecurity company pointed to growing demand for cyber resilience in an AI-driven threat environment.
Chief Executive Officer Bipu
ServiceTitan (NASDAQ:TTAN) reported 25% year-over-year revenue growth for its fiscal first quarter of 2027, as executives said the company benefited from healthy demand across residential and commercial trades, stronger gross transaction volume and early traction for its AI-focused Max offering.
Co
Guidewire Software (NYSE:GWRE) reported stronger-than-expected fiscal third-quarter revenue, profitability and cash flow, while management said demand for cloud migrations, pricing tools and AI-related products continued to build heading into the company’s seasonally important fourth quarter.
Chief
Samsara (NYSE:IOT) reported a strong start to fiscal 2027, with executives highlighting accelerating growth among large customers, expanding adoption of emerging products and continued profitability during the company’s first-quarter earnings call.
Chief Executive Officer and Co-founder Sanjit Bisw
Planet Labs PBC (NYSE:PL) reported record first-quarter fiscal 2027 revenue and raised its full-year sales outlook, citing strong demand from defense and intelligence customers, international governments seeking sovereign space capabilities, and expanding use of its AI-enabled geospatial products.
Cooper Companies (NASDAQ:COO) reported record revenue and non-GAAP earnings for its fiscal second quarter of 2026, while management said it is advancing discussions with multiple parties interested in CooperSurgical as part of its strategic review.
President and Chief Executive Officer Albert White
Docusign (NASDAQ:DOCU) reported 9% year-over-year revenue growth in the first quarter of fiscal 2027 and said adoption of its AI-native Intelligent Agreement Management platform, or IAM, continued to expand across its customer base.
CEO Allan Thygesen said on the company’s earnings call that Docusi
Torrid (NYSE:CURV) reported first-quarter fiscal 2026 sales slightly above its guidance and adjusted EBITDA at the high end of its outlook, while management said ongoing initiatives around store optimization, pricing and marketing are intended to position the plus-size apparel retailer for comparabl
Autodesk (NASDAQ:ADSK) executives said the company’s recently announced acquisition of MaintainX is intended to extend its software strategy from design and construction into the operations phase of an asset’s life cycle, positioning the company to address a larger market tied to maintenance and fac
Argan (NYSE:AGX) reported record fiscal first-quarter revenue and sharply higher earnings, as construction activity accelerated across its power projects and the company benefited from improved project execution and margins.
On the company’s earnings call for the first quarter of fiscal 2027, ended
Wealthfront (NASDAQ:WLTH) reported higher year-over-year revenue and record platform assets in its fiscal first quarter, while management said the company continued to invest in product expansion, including home lending, cash management features and artificial intelligence-related capabilities.
The
Zumiez (NASDAQ:ZUMZ) reported higher first-quarter sales and improved margins for fiscal 2026, but executives said consumer discretionary spending pressure intensified late in the quarter and continued into May, prompting a cautious outlook for the second quarter.
Chief Executive Officer Rick Brook
Concrete Pumping (NASDAQ:BBCP) reported stronger second-quarter results and raised its fiscal 2026 outlook, citing continued momentum in U.S. commercial and infrastructure markets, improved fleet utilization and growing work tied to data centers and chip plants.
On the company’s earnings call for t
lululemon athletica (NASDAQ:LULU) reported modest first-quarter revenue growth but lowered its fiscal 2026 outlook, citing softer recent sales trends, negative media and social commentary around the brand, and product launches that did not meet expectations.
Meghan Frank, interim co-CEO and chief f
Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting upcoming readouts across its immunology pipeline and a planned Phase 2 asthma study for its lead bispe
HPE's Q2 revenue surged 40% to $10.7 billion with a record $5.9 billion AI backlog, while Super Micro pivots to edge computing to defend its market position.
Adicet Bio (NASDAQ:ACET) outlined its near-term clinical priorities and upcoming data catalysts during a fireside chat at the Jefferies Healthcare Conference in New York, with President and CEO Chen Schor emphasizing the company’s focus on off-the-shelf gamma delta 1 T-cell therapies for autoimmune
Generac's strategic pivot into the AI data center market is solidified by a new global supply agreement that positions it as a key player in grid resilience.
AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said during a company presentation focused on the biotech’s pipeline and lead clinical program.
Booth said
Toro (NYSE:TTC) raised its full-year outlook after reporting stronger-than-expected fiscal second-quarter results, with executives pointing to broad demand across its professional and residential businesses, improving margins and benefits from its productivity initiatives.
Chairman and Chief Execut
X-Energy (NASDAQ:XE) used its first earnings call as a public company to outline progress on its advanced nuclear reactor and fuel businesses, while reporting higher first-quarter revenue and grant income tied to its federal cost-share program.
The company began trading on the Nasdaq on April 24 an
Brown Forman (NYSE:BF.A) said it finished fiscal 2026 ahead of its organic expectations, despite continued pressure from weaker discretionary spending in the U.S. and developed international markets, lower used barrel sales and the ongoing absence of American spirits from many Canadian shelves.
Pre
PVH (NYSE:PVH) said it met or exceeded its key first-quarter financial targets, helped by growth in direct-to-consumer sales and e-commerce, but lowered its full-year revenue outlook because of what executives described as the prolonged effects of the Middle East conflict on its EMEA business.
Chie
Columbus McKinnon (NASDAQ:CMCO) reported what management described as a “defining year” in fiscal 2026, highlighted by the completion of its Kito Crosby acquisition and the divestiture of its legacy U.S. power chain hoist and chain operations.
On the company’s fourth-quarter and full-year earnings
Weiss Ratings analyst Chris Graebe outlines how Regulation A offerings let retail investors access private companies like FJET, NUCL, and CNXU before their public listings.
Rising DRAM and NAND memory costs are pressuring margins at Nintendo and Sony while posing indirect launch risks for Take-Two Interactive's GTA6 release.
